US 12,005,045 B2
Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds
Pottayil Govindan Nair Sasikumar, Bangalore (IN); Muralidhara Ramachandra, Bangalore (IN); Seetharamaiah Setty Sudarshan Naremaddepalli, Bangalore (IN); and Chennakrishnareddy Gundala, Bangalore (IN)
Assigned to AURIGENE ONCOLOGY LIMITED, Karnataka (IN)
Filed by AURIGENE ONCOLOGY LIMITED, Bangalore (IN)
Filed on Nov. 22, 2023, as Appl. No. 18/518,292.
Application 18/518,292 is a continuation of application No. 17/045,916, previously published as PCT/IB2019/052039, filed on Mar. 13, 2019.
Claims priority of application No. 201841009306 (IN), filed on Mar. 14, 2018.
Prior Publication US 2024/0122904 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4245 (2013.01) [A61P 35/00 (2018.01)] 19 Claims
 
1. A method of modulating T cell immunoreceptor with Ig and ITIM domains (TIGIT) signaling pathway and programmed cell death 1 (PD-1) signaling pathway in a subject in need thereof, comprising administering to the subject Compound 19:

OG Complex Work Unit Chemistry
or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.